Preclinical News and Research

RSS
Banook Central Imaging, Oncodesign partner to expand use of new approaches in pharmaco-imaging

Banook Central Imaging, Oncodesign partner to expand use of new approaches in pharmaco-imaging

10 Sep 2013
Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

10 Sep 2013
Oncodesign, Banook Central Imaging To Develop Cancer Biomarkers

Oncodesign, Banook Central Imaging To Develop Cancer Biomarkers

9 Sep 2013
Researchers start Phase I clinical trial of implantable vaccine for treatment of melanoma

Researchers start Phase I clinical trial of implantable vaccine for treatment of melanoma

7 Sep 2013
Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

7 Sep 2013
Disease Twofer: Parkin Problem Leads To Parkinson’S And Impairs Response To TB

Disease Twofer: Parkin Problem Leads To Parkinson’S And Impairs Response To TB

5 Sep 2013
Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

5 Sep 2013
ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

5 Sep 2013
Blood levels of cystatin C strengthen association between kidney function and risks of renal disease

Blood levels of cystatin C strengthen association between kidney function and risks of renal disease

5 Sep 2013
Parkin protein plays key role in destruction of bacteria that cause tuberculosis

Parkin protein plays key role in destruction of bacteria that cause tuberculosis

5 Sep 2013
Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

Neurodyn acquires all assets related to new drug candidate Memogain from Galantos Pharma

5 Sep 2013
University of Leeds to study mechanism of Prana’s PBT434 in animal models of Parkinson’s disease

University of Leeds to study mechanism of Prana’s PBT434 in animal models of Parkinson’s disease

4 Sep 2013
Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

Aliskiren does not slow progression of coronary atherosclerosis in prehypertension patients

4 Sep 2013
Researchers discover new way to target senescent cancer cells for destruction

Researchers discover new way to target senescent cancer cells for destruction

4 Sep 2013
Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

Enanta Gets Additional $9.2M Toward Biodefense Antibiotic Development

3 Sep 2013
Viralytics releases financial results for 2013

Viralytics releases financial results for 2013

3 Sep 2013
Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

3 Sep 2013
Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

Renin inhibitor aliskiren not effective in slowing progression of coronary atherosclerosis

3 Sep 2013
Novel metabolic imaging method enhances prostate cancer diagnosis

Novel metabolic imaging method enhances prostate cancer diagnosis

2 Sep 2013
Researchers develop model that completes bridge between cellular and human studies of schizophrenia

Researchers develop model that completes bridge between cellular and human studies of schizophrenia

31 Aug 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback